| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The control ADC does not have a specific antigen target. The antibody moiety is a human IgG1 kappa isotype control selected to have minimal or no binding to human or mouse tissues. The drug‑linker component (sulfo‑SPDB‑DM4) targets tubulin. DM4 is a potent maytansinoid that binds to tubulin at the rhizoxin binding site, inhibiting microtubule polymerization and causing G2/M cell cycle arrest and apoptosis. The sulfo‑SPDB linker is a reducible disulfide linker designed to release DM4 inside target cells after internalization. However, the lack of targeting means that any activity is non‑specific.
|
|---|---|
| ln Vitro |
In vitro, the ADC Control Human IgG1‑sulfo‑SPDB‑DM4 serves as a negative control for target‑specific ADCs. In a cytotoxicity assay using antigen‑positive cancer cells (e.g., CanAg‑expressing cells), the control ADC (0.01‑10 ug/mL) should have no significant cytotoxic activity, while the experimental ADC (targeting the antigen) will be highly cytotoxic (IC₅0 in the ng/mL range). In an MTT assay using HepG2 cells, the control ADC may show some toxicity at very high concentrations (>10 ug/mL) due to non‑specific uptake (pinocytosis), but it should be significantly less potent than the experimental ADC. It is not used to assess the biological activity of the payload; rather, it is used as a comparator.
|
| ln Vivo |
In vivo, the control ADC is used as a negative control in mouse xenograft models. In a tumor xenograft model expressing the target antigen, the control ADC (3‑10 mg/kg, i.v.) should have no effect on tumor growth (TGI <20%) compared to vehicle control. The experimental ADC should show significant anti‑tumor activity (TGI >50%). This demonstrates that the anti‑tumor activity of the experimental ADC is target‑dependent and not due to non‑specific toxicity of the linker‑payload. The control ADC also helps assess non‑specific toxicity, such as body weight loss or hepatotoxicity.
|
| Enzyme Assay |
General in vitro cell viability assay (CellTiter‑Glo): Seed antigen‑positive cancer cells in 96‑well white plates at 5×103 cells/well. After 24 h, treat with serial dilutions of ADC Control Human IgG1‑sulfo‑SPDB‑DM4 (0.0001, 0.001, 0.01, 0.1, 1, 10 ug/mL) for 96 h. Add CellTiter‑Glo reagent and measure luminescence. The control ADC should have an IC₅0 >1 ug/mL (or not reached). Compare with experimental ADC (target‑specific), which should have an IC₅0 <0.1 ug/mL. For a flow cytometry binding assay, incubate target cells with control ADC (1‑10 ug/mL) on ice for 30 min, wash, and stain with anti‑human IgG‑FITC. The control ADC should show no binding (MFI similar to secondary antibody only). Experimental ADC should show strong binding.
|
| Cell Assay |
General in vitro stability assay: Incubate ADC Control Human IgG1‑sulfo‑SPDB‑DM4 (1 mg/mL) in human plasma at 37degC for 0, 24, 48, 72, 96 h. At each time point, collect samples, immunoprecipitate the ADC, and analyze by size‑exclusion HPLC to monitor aggregation. Additionally, measure DM4 release by LC‑MS after reduction with DTT. The control ADC should be stable in plasma for at least 72 h (<5% release of free DM4). For in vivo stability, administer the control ADC to mice and measure plasma DM4 levels; low levels indicate linker stability.
|
| Animal Protocol |
General in vivo protocol for isotype control validation: Female NCr nu/nu mice (n=8 per group) are inoculated subcutaneously with antigen‑positive tumor cells. When tumors reach 150‑200 mm3, administer ADC Control Human IgG1‑sulfo‑SPDB‑DM4 (3, 10 mg/kg, i.v., single dose). Control groups receive vehicle (PBS or histidine buffer) and experimental ADC (3 mg/kg). Measure tumor volume twice weekly for 28 days. The control ADC should show no significant tumor growth inhibition (TGI <20%). At the end of the study, harvest tumors and major organs for histopathology. No significant toxicity should be observed. The control ADC should also not cause significant body weight loss.
|
| ADME/Pharmacokinetics |
ADC Control Human IgG1‑sulfo‑SPDB‑DM4 is a complete ADC molecule (MW ~150 kDa) and is administered intravenously for in vivo studies. The pharmacokinetics (PK) are expected to be similar to any human IgG1 antibody, with a half‑life of 4‑7 days in mice. The sulfo‑SPDB linker is designed to be stable in circulation but reducible in the intracellular environment. However, as a control, its PK is not the primary focus. For research use, the control ADC is supplied as a sterile solution in PBS, stored at 4degC for short‑term use and at ‑80degC for long‑term storage. Avoid repeated freeze‑thaw cycles.
|
| Toxicity/Toxicokinetics |
The control ADC has manageable toxicity. At therapeutic doses (3‑10 mg/kg), it is well‑tolerated. Higher doses (>30 mg/kg) may cause toxicity due to the DM4 payload (e.g., weight loss, myelosuppression). It is not genotoxic. For use as a research reagent, standard safety precautions (gloves, lab coat) for handling biological materials are sufficient.
|
| References | |
| Additional Infomation |
Background: This is an isotype control for ADCs using a sulfo‑SPDB‑DM4 linker‑payload. It is essential for interpreting ADC efficacy studies, allowing researchers to distinguish specific, target‑dependent effects from non‑specific, Fc‑mediated, or linker‑mediated effects. The sulfo‑SPDB linker is a reducible disulfide linker that releases DM4 upon internalization into cells (via thiol exchange). The isotype control antibody is human IgG1 kappa. It is for research use only, not for human therapy.
|
| Appearance |
Colorless to light yellow liquid
|
|---|---|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
